Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTG-021
- Development stage
- Unknown
- Lead developer
- PolTREG
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intrathecal
01
Overview
PTG-021 (anti-MOG CAR-Tregs) is an investigational autologous chimeric antigen receptor regulatory T-cell (CAR-Treg) therapy being developed by PolTREG and its subsidiary Immuthera for the treatment of neuroinflammatory and neurodegenerative diseases, including primary progressive multiple sclerosis (PPMS) and amyotrophic lateral sclerosis (ALS). The therapy consists of CD4+CD25+CD127- regulatory T cells genetically engineered to express a second-generation CAR targeting myelin oligodendrocyte glycoprotein (MOG), a key autoantigen in central nervous system demyelination. Administered intrathecally, PTG-021 is designed to migrate to sites of neuroinflammation, where MOG binding activates the CAR-Tregs to suppress autoreactive T-cell and antigen-presenting cell responses, thereby promoting immune tolerance and protecting myelin sheaths from autoimmune destruction. PTG-021 is prepared for Phase I/IIa clinical evaluation.
- Other names
- MOG-CAR+ TregMOG-CAR-Tregsanti-MOG CAR-Tregs
02
Targets
MOG (Myelin oligodendrocyte glycoprotein)
Beyond the preview
Go deeper on PTG-021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTG-021.